SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Langkilde Anna M.)
 

Sökning: WFRF:(Langkilde Anna M.) > (2020) > The dapagliflozin a...

The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial : baseline characteristics

Wheeler, David C. (författare)
UCL, Dept Renal Med, London, England.
Stefansson, Bergur, V (författare)
AstraZeneca, BioPharmaceut R&D, Late Stage Dev Cardiovasc Renal & Metab, Gothenburg, Sweden.
Batiushin, Mikhail (författare)
Rostov State Med Univ, Dept Nephrol, Rostov Na Donu, Russia.
visa fler...
Bilchenko, Oleksandr (författare)
Kharkiv Med Acad Postgrad Educ, Kharkiv, Ukraine.
Cherney, David Z., I (författare)
Univ Hlth Network, Toronto Gen Hosp Res Inst, Toronto, ON, Canada.;Univ Toronto, Dept Med, Div Nephrol, Toronto, ON, Canada.
Chertow, Glenn M. (författare)
Stanford Univ, Dept Epidemiol & Populat Hlth, Sch Med, Stanford, CA USA.;Stanford Univ, Dept Med, Sch Med, Stanford, CA USA.
Douthat, Walter (författare)
Hosp Privado Univ Cordoba, Dept Nephrol, Cordoba, Argentina.
Dwyer, Jamie P. (författare)
Vanderbilt Univ, Med Ctr, Nashville, TN USA.
Escudero, Elizabeth (författare)
Cayetano Heredia Univ, Hosp Arzobispo Loayza, Div Nephrol, Lima, Peru.
Pecoits-Filho, Roberto (författare)
Pontificia Univ Catolica Parana, Sch Med, Curitiba, Parana, Brazil.;Arbor Res Collaborat Hlth, Ann Arbor, MI USA.
Furuland, Hans (författare)
Uppsala universitet,Njurmedicin
Gorriz, Jose Luis (författare)
Univ Valencia, Univ Clin Hosp, Dept Nephrol, INCLIVA, Valencia, Spain.
Greene, Tom (författare)
Univ Utah Hlth Sci, Study Design & Biostat Ctr, Salt Lake City, UT USA.
Haller, Hermann (författare)
Hannover Med Sch, Hannover, Germany.
Hou, Fan Fan (författare)
Southern Med Univ, Natl Clin Res Ctr Kidney Dis, Dept Med, Div Nephrol, Guangzhou, Peoples R China.
Kang, Shin-Wook (författare)
Yonsei Univ, Dept Internal Med, Div Nephrol, Coll Med, Seoul, South Korea.
Isidto, Rey (författare)
Healthlink Med Dent Surg Clin & Diagnost Ctr, Iloilo, Philippines.
Khullar, Dinesh (författare)
Max Super Special Hosp, Dept Nephrol & Renal Transplant Med, New Delhi, India.
Mark, Patrick B. (författare)
Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland.
McMurray, John J., V (författare)
Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland.
Kashihara, Naoki (författare)
Kawasaki Med Sch, Dept Nephrol & Hypertens, Okayama, Japan.
Nowicki, Michal (författare)
Med Univ Lodz, Dept Nephrol Hypertens & Kidney Transplantat, Lodz, Poland.
Persson, Frederik (författare)
Steno Diabet Ctr Copenhagen, Gentofte, Denmark.
Correa-Rotter, Ricardo (författare)
Natl Med Sci & Nutr Inst Salvador Zubiran, Mexico City, DF, Mexico.
Rossing, Peter (författare)
Steno Diabet Ctr Copenhagen, Gentofte, Denmark.;Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark.
Toto, Robert D. (författare)
UT Southwestern Med Ctr, Dept Internal Med, Dallas, TX USA.
Umanath, Kausik (författare)
Henry Ford Hosp, Div Nephrol & Hypertens, Detroit, MI 48202 USA.;Wayne State Univ, Div Nephrol & Hypertens, Detroit, MI USA.
Van Bui, Pham (författare)
Pham Ngoc Thach Med Univ, Ho Chi Minh City, Vietnam.
Wittmann, Istvan (författare)
Univ Pecs, Dept Med 2, Med Sch, Pecs, Hungary.;Univ Pecs, Nephrol Diabet Ctr, Med Sch, Pecs, Hungary.
Lindberg, Magnus (författare)
AstraZeneca, BioPharmaceut R&D, Late Stage Dev Cardiovasc Renal & Metab, Gothenburg, Sweden.
Sjostrom, C. David (författare)
AstraZeneca, BioPharmaceut R&D, Late Stage Dev Cardiovasc Renal & Metab, Gothenburg, Sweden.
Langkilde, Anna Maria (författare)
AstraZeneca, BioPharmaceut R&D, Late Stage Dev Cardiovasc Renal & Metab, Gothenburg, Sweden.
Heerspink, Hiddo J. L. (författare)
Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands.
visa färre...
UCL, Dept Renal Med, London, England AstraZeneca, BioPharmaceut R&D, Late Stage Dev Cardiovasc Renal & Metab, Gothenburg, Sweden. (creator_code:org_t)
2020-08-30
2020
Engelska.
Ingår i: Nephrology, Dialysis and Transplantation. - OXFORD ENGLAND : Oxford University Press (OUP). - 0931-0509 .- 1460-2385. ; 35:10, s. 1700-1711
Relaterad länk:
https://doi.org/10.1...
visa fler...
https://academic.oup...
https://urn.kb.se/re...
https://doi.org/10.1...
visa färre...
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Background. The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD; NCT03036150) trial was designed to assess the effect of the sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin on kidney and cardiovascular events in participants with CKD with and without type 2 diabetes (T2D). This analysis reports the baseline characteristics of those recruited, comparing them with those enrolled in other trials. Methods. In DAPA-CKD, 4304 participants with a urinary albumin:creatinine ratio (UACR) <= 200mg/g and estimated glomerular filtration rate (eGFR) between 25 and 75mL/min/1.73m(2) were randomized to dapagliflozin 10mg once daily or placebo. Mean eGFR was 43.1mL/min/1.73m(2) and median UACR was 949 mg/g (108mg/mmol). Results. Overall, 2906 participants (68%) had a diagnosis of T2D and of these, 396 had CKD ascribed to a cause other than diabetes. The most common causes of CKD after diabetes (n = 2510) were ischaemic/hypertensive nephropathy (n = 687) and chronic glomerulonephritis (n = 695), of which immunoglobulin A nephropathy (n = 270) was the most common. A total of 4174 participants (97%) were receiving an angiotensinconverting enzyme inhibitor or angiotensin receptor blocker, 1882 (43.7%) diuretics, 229 (5.3%) mineralocorticoid receptor antagonists and 122 (2.8%) glucagon-like peptide 1 receptor agonists. In contrast to the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), the DAPA-CKD trial enrolled participants with CKD due to diabetes and to causes other than diabetes. The mean eGFR of participants in the DAPA-CKD trial was 13.1mL/min/1.73m(2) lower than in CREDENCE, similar to that in the Finerenone in Reducing Kidney Failure and Disease Progression in DKD (FIDELIO-DKD) trial and the Study Of diabetic Nephropathy with AtRasentan (SONAR). Conclusions. Participants with a wide range of underlying kidney diseases receiving renin-angiotensin system blocking therapy have been enrolled in the DAPA-CKD trial. The trial will examine the efficacy and safety of dapagliflozin in participants with CKD Stages 2-4 and increased albuminuria, with and without T2D.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Urology and Nephrology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)

Nyckelord

chronic kidney disease
dapagliflozin
randomized controlled clinical trial
sodium-glucose co-transporter-2 inhibitor

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy